Literature DB >> 31418417

Claudin-9 enhances the metastatic potential of hepatocytes via Tyk2/Stat3 signaling.

Hongyu Liu1, Min Wang2, Na Liang3, Lianyue Guan1.   

Abstract

BACKGROUND/AIMS: We have previously identified a tight junction protein claudin-9 (CLDN9) as an upregulated gene in hepatocellular carcinoma (HCC) through an immunohistochemistry analysis. Here, we explore its function and clinical relevance in human HCC.
MATERIALS AND METHODS: Stable transfection of the hepatocyte line HL7702 with CLDN9 was confirmed by the real-time polymerase chain reaction (PCR), western blotting, and immunofluorescence. The impact of CLDN9 on the cell invasion and migration was assessed in vitro by a transwell assay and wound-healing experiment. Western blotting was used to determine the activation state of the Tyk2 (tyrosine kinase 2)/Stat3 (signal transducer and activator of transcription 3) pathway. Moreover, we used a Tyk2-RNAi assay to silence the expression of Tyk2 in CLDN9 expressing hepatocytes; subsequently, the impact of the Tyk2/Stat3 signaling pathway on the cell invasion and migration in vitro was assessed by a transwell assay and a wound-healing experiment. Furthermore, an immunohistochemistry method was utilized to explore the expression levels of CLDN9 and p-Stat3 in the HCC tissues and histologically non-neoplastic hepatic tissues.
RESULTS: We confirmed that the expression of CLDN9 significantly enhanced the metastatic ability of hepatocytes in vitro, and the activation of the Stat3 pathway by Tyk2 was an important mechanism by which CLDN9 promoted hepatocyte aggressiveness in HCC.
CONCLUSION: As an HCC proto-oncogene, CLDN9 affected the Stat3 signaling pathway via Tyk2 and ultimately enhanced the metastatic ability of hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31418417      PMCID: PMC6699577          DOI: 10.5152/tjg.2019.18513

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  25 in total

Review 1.  Structural and signalling molecules come together at tight junctions.

Authors:  S Tsukita; M Furuse; M Itoh
Journal:  Curr Opin Cell Biol       Date:  1999-10       Impact factor: 8.382

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes.

Authors:  S Tabariès; Z Dong; M G Annis; A Omeroglu; F Pepin; V Ouellet; C Russo; M Hassanain; P Metrakos; Z Diaz; M Basik; N Bertos; M Park; C Guettier; R Adam; M Hallett; P M Siegel
Journal:  Oncogene       Date:  2010-11-15       Impact factor: 9.867

Review 4.  Claudins: multifunctional players in epithelial tight junctions and their role in cancer.

Authors:  S S Oliveira; J A Morgado-Díaz
Journal:  Cell Mol Life Sci       Date:  2007-01       Impact factor: 9.261

Review 5.  Crosstalk of tight junction components with signaling pathways.

Authors:  Lorenza González-Mariscal; Rocio Tapia; David Chamorro
Journal:  Biochim Biophys Acta       Date:  2007-09-04

6.  Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer.

Authors:  Viola A Heinzelmann-Schwarz; Margaret Gardiner-Garden; Susan M Henshall; James Scurry; Richard A Scolyer; Michael J Davies; Matthias Heinzelmann; Larry H Kalish; Anish Bali; James G Kench; Lyndal S Edwards; Patricia M Vanden Bergh; Neville F Hacker; Robert L Sutherland; Philippa M O'Brien
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

7.  Claudin family of proteins and cancer: an overview.

Authors:  Amar B Singh; Ashok Sharma; Punita Dhawan
Journal:  J Oncol       Date:  2010-07-08       Impact factor: 4.375

8.  Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma.

Authors:  Yu-Chih Chao; Szu-Hua Pan; Shuenn-Chen Yang; Sung-Liang Yu; Ting-Fang Che; Chung-Wu Lin; Mu-Shiun Tsai; Gee-Chen Chang; Che-Hsiang Wu; Yi-Ying Wu; Yung-Chie Lee; Tse-Ming Hong; Pan-Chyr Yang
Journal:  Am J Respir Crit Care Med       Date:  2008-09-11       Impact factor: 21.405

Review 9.  Claudins in human cancer: a review.

Authors:  Abderrahman Ouban; Atif A Ahmed
Journal:  Histol Histopathol       Date:  2010-01       Impact factor: 2.303

Review 10.  The Claudin family and its role in cancer and metastasis.

Authors:  Astrid Escudero-Esparza; Wen G Jiang; Tracey A Martin
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01
View more
  6 in total

1.  The expression and the tumor suppressor role of CLDN6 in colon cancer.

Authors:  Huinan Qu; Min Wang; Miaomiao Wang; Yuanyuan Liu; Chengshi Quan
Journal:  Mol Cell Biochem       Date:  2022-06-14       Impact factor: 3.396

Review 2.  TYK2: An Upstream Kinase of STATs in Cancer.

Authors:  Katharina Wöss; Natalija Simonović; Birgit Strobl; Sabine Macho-Maschler; Mathias Müller
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

3.  Identification and validation of a glycolysis-associated multiomics prognostic model for hepatocellular carcinoma.

Authors:  Tuo Deng; Qian Ye; Chen Jin; Mingliang Wu; Kaiyu Chen; Jinhuan Yang; Ziyan Chen; XiXiang Yu; Gang Chen; Yi Wang
Journal:  Aging (Albany NY)       Date:  2021-03-03       Impact factor: 5.682

4.  Comprehensive Analysis of the Glycolysis-Related Gene Prognostic Signature and Immune Infiltration in Endometrial Cancer.

Authors:  Xiao Yang; Xingchen Li; Yuan Cheng; Jingyi Zhou; Boqiang Shen; Lijun Zhao; Jianliu Wang
Journal:  Front Cell Dev Biol       Date:  2022-02-11

5.  Clinical and molecular features of sacrum chordoma in Chinese patients.

Authors:  Zonghan Xu; Ling Zhang; Lijun Wen; Zheng Wang; Jian Lu; Hongying Chao; Qinrong Wang; Miao Sun; Hongjie Shen; Suning Chen
Journal:  Ann Transl Med       Date:  2022-01

6.  Claudin‑9 is a novel prognostic biomarker for endometrial cancer.

Authors:  Yuta Endo; Kotaro Sugimoto; Makoto Kobayashi; Yasuyuki Kobayashi; Manabu Kojima; Shigenori Furukawa; Shu Soeda; Takafumi Watanabe; Atsuko Y Higashi; Tomohito Higashi; Yuko Hashimoto; Keiya Fujimori; Hideki Chiba
Journal:  Int J Oncol       Date:  2022-09-21       Impact factor: 5.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.